Samsung Biologics shares fly high to be Korea’s third most valuable firm
Samsung Biologics Co., the world’s largest contract drugmaker, has become South Korea’s third most valuable stock on the country’s...
Samsung Biologics posts record 2024 sales, operating profit as it goes global
South Korea's Samsung Biologics Co., the world’s largest contract drugmaker, on Wednesday posted its largest-ever annual sales and operating p...
Korean drugmakers control more than half of European biosimilar market
South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar...
Daewoong wins permission for Nabota in Argentina
South Korea's Daewoong Pharmaceutical Co. announced on Monday that its botulinum toxin Nabota received product approval from Argentina's National Ad...
S.Korean anti-obesity drugmakers eye niche demand
The global weight management market has entered a new chapter following the arrival of blockbuster weight-loss medication Wegovy, and South Korean l...
Celltrion'a autoimmune disease drug Zymfentra makes US debut
South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...
Samsung Biologics eyes new drugmaker acquisitions
BARCELONA -- Samsung Biologics Co., the world’s top contract manufacturing organization by capacity, is looking for acquisitions of new drugma...
Celltrion’s approved merger removes hurdle to three-way combination
South Korea’s biosimilar drugmaker Celltrion group on Monday moved one step closer to the planned combination of its three major affiliates wi...
IMM PE seeks to sell Korean contract drugmaker at $784 mn
IMM Private Equity has put a South Korean contract drugmaker on the market for up to 1 trillion won ($784 million) in a deal likely to attract major...
Samsung Biologics wins $897 mn in two deals with Pfizer
Samsung Biologics Co., the world’s largest contract manufacturing organization (CMO) in terms of production capacity, said on Tuesday it has w...
LegoChem Bio receives FDA approval for phase 1,2 trials of LCB84
South Korean pharmaceutical firm LegoChem Biosciences Inc. announced on Thursday that it has received approval from the US Food and Drug Administrat...
Daewoong Pharma wins permission from Singapore for Nabota
South Korea's drug development company Daewoong Pharmaceutical said on Thursday that it received on Jan. 20 product approval for its botulinum toxin...
JW Pharma to put AI into new drug ingredient development
South Korea's drug developer JW Pharmaceutical is expanding the scope of its artificial intelligence (AI) uses from new drug research to the develop...
Celltrion increases its stake in British ADC developer Iksuda
Celltrion Inc. has secured an additional stake in the UK's antibody-drug conjugate (ADC) developer Iksuda Therapeutics.According to Celltrion on Wed...
Celltrion targets digital healthcare sector with app
Celltrion Inc., South Korea’s biopharmaceutical giant, made a foray into the digital healthcare sector for its future growth by launching a sm...
Celltrion wins sales approval for biosimilar Vegzelma in Japan
Celltrion Inc. secured Japan’s approval for sales of its cancer treatment biosimilar CT-P16, a move to help the South Korean biopharmaceutical...
Celltrion logs strong Q2 earnings powered by biosimilars
South Korea’s biopharmaceutical maker Celltrion Inc. on Friday reported strong quarterly earnings thanks to healthy demand for its biosimilar ...
Korean drugmakers close to commercializing COVID-19 vaccine, pill
South Korea’s biopharmaceutical companies are close to commercializing a COVID-19 vaccine and treatment pill as they are on the brink of compl...
Hanmi stands out with own drugs as Korean rivals sell imports
South Korea’s Hanmi Pharmaceutical Co. generated sales of more than 1 trillion won ($812.3 million) from its own medicines last year on strong...
Samsung Biologics wins another Eli Lilly COVID treatment order
Samsung Biologics Co., a global contract development and manufacturing organization (CDMO), has stepped up its partnerships with global big pharmas ...
Korean drugmakers race to release Stelara biosimilars
South Korea’s major drugmakers such as Celltrion Inc., Samsung Bioepis and Dong-A St are going for broke to release biosimilars of Stelara, Jo...
